Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAetna Part B preferred drug list Coverage & Prior …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy Y0001_NR_4168512_2025_C 4168504-01-01

    Medicare Part B preferred drug list — Aetna Medicare Advantage (MA) only plans

    Customize your policy alerts

    Sign up for Aetna Policy Y0001_NR_4168512_2025_C 4168504-01-01 alerts

    Get alerted when Policy Y0001_NR_4168512_2025_C 4168504-01-01 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists preferred and non-preferred medically administered Part B drugs by therapeutic category for Aetna Medicare Advantage plans and describes that some drugs are subject to step therapy, prior authorization, or other limits. Affects providers ordering/administering Medicare Part B drugs for Aetna MA members.

    Policy Summary
    PayerAetna
    PolicyMedicare Part B preferred drug list — Aetna Medicare Advantage (MA) only plans
    Policy CodePolicy Y0001_NR_4168512_2025_C 4168504-01-01
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit required medical necessity criteria and the specified fax request form when requesting non-preferred or step therapy‑subject Part B drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipletherapeutic categories listed (partial document)
    step therapy mentionedpolicy uses step therapy for some Part B drugs
    examplesexamples where prior auth is not required
    20+distinct drug entries referenced
    multipledistinct HCPCS / Q-code mappings shown

    Coverage Criteria and General Policy Rules

    General Step Therapy/Preferred Product Requirement

    Covered when meeting step therapy and medical necessity criteria as specified for each drug/indication

    General requirement: Provider must trial preferred product(s) listed for the drug class before a non-preferred product will be covered, except where an exception applies.trial of preferred drug(s)

    Exception process available

    Prior Authorization Not Required (examples)

    Certain preferred drugs are designated as not requiring prior authorization

    No prior auth examples: Zoledronic acid (J3489) and Zarxio (Q5101) are listed as prior authorization not required.N/A

    Refer to specific drug entries for full requirements

    Coverage contingent on medical necessity and step therapy links

    Products covered when meeting referenced medical necessity and step therapy criteria

    General step therapy requirement: Coverage for listed indications (e.g., Hemophilia A prophylaxis; immunologic indications such as ulcerative colitis and Crohn's disease) is contingent on meeting the referenced medical necessity criteria and step therapy rules as noted per product grouping (preferred vs non-preferred).

    Specific product-level links to criteria or 'Prior authorization not required' flags are included in the product entries.

    Prior authorization not required entries

    Exceptions noted

    Products without prior authorization: Some drugs (example: Eligard, J9217) are explicitly noted as not requiring prior authorization, implying coverage without PA when indication and billing align with the listed entry.

    Verify that clinical indication and billing align with the entry

    Product-level coverage references

    Covered when following product-specific criteria (as referenced); many entries require meeting linked medical necessity criteria and may be subject to step therapy

    Agent listed with medical necessity link: Agent is included on the preferred/non-preferred Part B list and authorization relies on the referenced 'Link to criteria' or stated step therapy status (e.g., Inflectra Q5103, Renflexis Q5104, Avsola Q5121, Avzivi J3590).see linked criteria

    This section lists many agents each with an associated 'Link to criteria', 'Step therapy criteria' or indicates 'None' if not applicable

    General coverage conditioned on linked criteria

    Covered when administrative and clinical criteria (linked) are met; many entries require prior authorization or step therapy documentation.

    General: Provider must submit medical necessity criteria and complete the fax request form when indicated; follow the step therapy links for specific required trials or failure definitions.

    See linked criteria per drug/category for exact requirements

    General coverage linkage to medical necessity and step therapy criteria

    Covered when medical necessity criteria or step therapy criteria (as linked) are met for each listed drug or category.

    Category or drug-level requirement: Each listed drug or category references either medical necessity criteria and/or step therapy criteria: providers must meet the specific linked criteria for coverage (examples include ophthalmic VEGF inhibitors, viscosupplements, octreotide depot, and lupus agents).

    Specific step therapy sequences and required prior trials are detailed in the referenced step therapy criteria documents.

    Preferred product and step therapy logic: the policy requires trial of listed preferred product(s) in a drug class before a non-preferred Part B product will be covered. An exception process is available for specific cases that may warrant a non-preferred product; providers should consult the referenced step therapy criteria documents for indication-specific rules and the exception pathway details.

    Within the extracted portions there are no formal, drug-level exclusion statements; non-preferred drugs are presented as grouped listings but this segment does not explicitly list products as excluded. Coverage determinations for non-preferred agents are governed by the linked medical necessity and step therapy criteria referenced in each product entry.

    Intravenous iron and other IV products: some IV iron products in the listing are identified as non-preferred and reference separate medical necessity/step therapy criteria. Providers should follow those referenced criteria for IV iron coverage decisions; when an IV iron is non-preferred, the linked criteria will indicate prior authorization or step therapy requirements.

    Examples of drugs that do not require prior authorization in these excerpts include Halaven (HCPCS J9179) and select chemotherapy or supportive agents listed as 'not required' for prior authorization. Also, the docetaxel and paclitaxel entries show differing PA expectations in this segment (see product rows for exact PA language). Always verify the per-drug entry for the explicit 'Prior authorization is not required' flag.

    Formulary and plan features may change over time. For a complete description of plan benefits, exclusions, limitations, and conditions of coverage, refer to the plan Evidence of Coverage; product availability and preferred designations are subject to change.

    This extract does not contain explicit 'not medically necessary' declarations for individual drugs. However, when required step therapy or referenced medical necessity criteria are not met, coverage may not be approved — the policy relies on the linked medical necessity criteria to define when a request is medically necessary.

    Many product entries in this document refer to separate medical necessity criteria documents or step therapy links rather than embedding full not-medically-necessary language. Where those linked medical necessity criteria apply, they govern whether an item meets coverage conditions; this extract does not itself state explicit 'not medically necessary' rulings.

    Docetaxel and paclitaxel PA notes in this segment are presented at the product-row level: the docetaxel row contains an incomplete PA statement in the excerpt while paclitaxel is shown as prior authorization not required in this portion. Providers must check the referenced product entry and linked criteria/fax form to confirm the current PA requirement.

    Requests that do not include required documentation — such as completion of specified step therapy trials or submission of the referenced medical necessity criteria and fax request form — may not meet coverage requirements and therefore may be denied. Providers should submit the linked criteria/fax form information when requesting authorization for non-preferred or step therapy–subject drugs.

    HCPCS/Q-code mappings and Code Lists

    Alpha-1 proteinase inhibitorsHCPCS
    J0256Prolastin-C / Zemaira (alpha-1 proteinase inhibitors) as listed
    J0257Glassia (alpha-1 proteinase inhibitor) listed
    Bone resorption inhibitors and related agentsHCPCS
    J3489Zoledronic acid
    J2430Pamidronate
    J0897Prolia / Xgeva (appear in bone resorption categories)
    J3111Evenity
    Q5136Jubbonti / Wyost (biosimilar-type codes listed)
    Botulinum toxinsHCPCS
    J0585Botox
    J0586Dysport
    J0587Myobloc
    J0588Xeomin
    J0589Daxxify
    8Q5159 Category code used repeatedly for botulinum toxins / other categories
    Complement inhibitors / Neurologic biologicsHCPCS
    J1299Soliris
    J1303Ultomiris
    Q5152Bkemv (code mapping shown)
    Q5151Epysqli (code mapping shown)
    J9332Vyvgart
    J9333Rystiggo
    J9334Vyvgart Hytrulo
    Colony stimulating factors (short- and long-acting) and biosimilarsHCPCS
    Q5101Zarxio
    J1447Granix
    J1442Neupogen
    J2506Neulasta
    Q5108Fulphila
    Q5130Fylnetra
    Q5122Nyvepria
    Enzyme replacement therapies and factor VIII productsHCPCS
    J1786Cerezyme
    J3060Elelyso
    J3385Vpriv
    J7211Kovaltry
    J7209Nuwiq
    J7192Advate
    Factor VIII / related HCPCS codes (examples)HCPCS
    J7211Kovaltry
    J7209Nuwiq
    J7192Advate
    J7210Afstyla
    J7182NovoEight
    J7185Xyntha
    Gonadotropin-releasing hormone agonists HCPCS examplesHCPCS
    J9217Eligard / Lupron depot (also listed J9217/J1950 for Lupron)
    J1950Lupron depot (listed conjointly)
    J3315Trelstar
    J9202Zoladex
    Immunologics / biologics HCPCS & Q-code mappingsHCPCS
    J3380Entyvio IV
    Q5103Inflectra
    Q5104Renflexis
    Q9997Pyzchiva IV
    J1628Tremfya IV
    Q5121Avsola
    J1745Remicade
    Q5098Imuldosa IV
    Q9999Otulfi IV
    Q9998Selarsdi IV
    1–10 of 25
    1/3
    Remicade/biosimilars and related agentsHCPCS
    Q5115Listed repeatedly as group/column identifier for entries in this segment
    Q5103HCPCS code mapping for Inflectra (Remicade biosimilar)
    Q5104HCPCS code mapping for Renflexis (Remicade biosimilar)
    J1602HCPCS code mapping for Simponi Aria
    Q5121HCPCS code mapping for Avsola
    J1745HCPCS code mapping for Remicade / Unbranded infliximab in some entries
    J0717HCPCS code mapping for Cimzia
    Intravenous ironHCPCS
    J2916Sodium ferric gluconate
    J1750Infed
    J1756Venofer
    Q0139Feraheme (alternate Q-code listed Q0139/Q0138)
    J1439Injectafer
    J1437Monoferric
    IVIG / SCIG productsHCPCS
    J1561Gammaked / Gamunex-C (IVIG/SCIG)
    J1459Privigen (IVIG)
    J1552Alyglo (IVIG)
    J1554Asceniv (IVIG)
    J1556Bivigam (IVIG)
    J1572Flebogamma (IVIG)
    J1569Gammagard Liquid (IVIG/SCIG)
    J1557Gammaplex (IVIG)
    J1568Octagam (IVIG)
    J1576Panzyga (IVIG)
    1–10 of 11
    1/2
    SCIG, MS, oncology agents and Avastin biosimilarsHCPCS
    J2350Ocrevus
    J2351Ocrevus Zunovo
    J0202Lemtrada
    J2329Non-preferred SCIG code referenced
    J2323Tysabri
    J9316Phesgo
    J9306Perjeta
    J9267Paclitaxel
    J9171Docetaxel
    J9264Abraxane / paclitaxel (protein-bound) mapping
    1–10 of 16
    1/2
    Oncology biosimilars and mappings (partial)HCPCS
    Q5107Listed mapping placeholder (multiple drugs mapped from/to Q5107 in these chunks)
    Q5118Zirabev mapping
    J9035Avastin
    J3590/C9399Avzivi
    PD1/PDL1 agentsHCPCS
    J9119Libtayo
    J9271Keytruda
    J9277Keytruda Qlex
    Multiple myeloma / chemotherapy agentsHCPCS
    J9046Bortezomib/Velcade (one of listed codes)
    J9047Kyprolis
    J9305Alimta (pemetrexed)
    Grouped J-code placeholders and steroid mappingsHCPCS
    J9294Grouped code placeholder used across multiple categories
    J9296Grouped code placeholder used across multiple categories
    J9297Grouped code placeholder used across multiple categories
    J9314Grouped code placeholder used across multiple categories
    J1010Methylprednisolone acetate
    Somatostatin analogues and lupus agentsHCPCS
    J1930Somatuline depot
    J2353Octreotide acetate depot / Sandostatin LAR
    J0490Benlysta
    J0491Saphnelo
    Part B drug HCPCS codes (examples in document)HCPCS
    J9294octreotide acetate depot (referenced grouping)
    J9296octreotide acetate depot (referenced grouping)
    J9297octreotide acetate depot (referenced grouping)
    J9314octreotide acetate depot (referenced grouping)
    J2353mapped code for octreotide depot / Sandostatin LAR reference
    J2502Signifor LAR reference
    J0490Benlysta (belimumab) reference
    J0491Saphnelo (anifrolumab) reference
    Ophthalmic and viscosupplement HCPCS codes listedHCPCS
    C9257Bevacizumab (Avastin) ophthalmic reference
    J7999bevacizumab billing reference
    Q5124Byooviz
    J0178Eylea
    J0177Eylea HD
    Q5147Pavblu
    Q5149Enzeevu
    Q5150Ahzantive
    Q5153Opuviz
    Q5155Yesafili
    1–10 of 28
    1/3
    Step therapy criteria presence
    Step therapy presencePer-drug entries indicate either 'Step therapy criteria = None' or a 'Link to criteria' — step therapy is applied where the entry references step therapy criteria; consult the linked step therapy criteria for the specific drug/indication.
    Examples labeled 'None'Some preferred agents are shown with 'Step therapy criteria = None' (e.g., Inflectra, Renflexis entries note 'None' for step therapy).

    What Providers Must Do (Prior Auth, Step Therapy, Fax Forms)

    Prior Authorization

    Confirm whether prior authorization is required for each product

    Prior authorization (PA) requirements differ by drug: some listed Part B drugs are explicitly noted as “Prior authorization is not required” (examples: Zoledronic acid J3489; Zarxio Q5101), while many other products reference linked medical necessity criteria or fax request forms that govern PA. Providers must check the specific product entry and its linked criteria/fax form to determine whether PA is required for that HCPCS/Q-code.

    • Zoledronic acid (J3489) — “Prior authorization is not required” and “Step therapy criteria = None” (see product entry).
    • Zarxio (Q5101) — listed as a preferred colony stimulating factor with “Prior authorization is not required.”
    • Many biosimilars and other HCPCS-coded agents include “Link to criteria” and “Link to fax form” indicating PA/medical necessity review is required per the linked documents.
    Prior Authorization

    Note products explicitly labeled 'PA not required' (e.g., Eligard J9217)

    Some individual products are specifically flagged as not requiring prior authorization (example: Eligard J9217). For other listed agents the product entry shows a link to medical necessity criteria — follow that entry to determine PA status.

    Initial Therapy and Step Requirements

    Initial step therapy requirement

    Preferred products should be used first in classes subject to step therapy

    Initial therapy requirement: Trial of listed preferred product(s) in the class is required prior to coverage of listed non-preferred products; see specific drug links for exact step therapy criteria.trial of preferred product(s)

    Exception process may allow non-preferred product

    Initial therapy — step therapy applies

    Step therapy applies for initial therapy in listed indications

    Step therapy general: Initial coverage for listed indications follows preferred-drug-first policies and step therapy rules as indicated; product-specific entries sometimes state 'Step therapy criteria = None' for preferred agents (e.g., Kovaltry J7211, Nuwiq J7209) and provide links for others.

    See product entries for 'Step therapy criteria = None' or links to criteria.

    Step Therapy Tables and Sequences

    RequirementSummary
    Trial of preferred product(s) required before covering non-preferred Part B drugs
    Preferred products listed for the drug class must be used first; an exception process exists for cases requiring non-preferred products
    Drugs / IndicationsStep therapy note
    Hemophilia A (prophylaxis) — Kovaltry (J7211), Nuwiq (J7209) listed as preferred; some non-preferred factor VIII products listed
    Immunologics for ulcerative colitis / Crohn's — Entyvio (J3380), Inflectra/Renflexis (Q5103/Q5104) noted as preferred; category marked 'Prior authorization is not required' for some entries
    Category: Bone resorption inhibitors — Zoledronic acid (J3489) listed with 'Prior authorization is not required'; 2nd-tier preferred/non-preferred sequencing specified
    Agent / CategoryStep therapy linkage
    Remicade and biosimilars (Inflectra Q5103, Renflexis Q5104, Avsola Q5121, Remicade J1745) — entries indicate 'Step therapy criteria = None' for some biosimilars and links to step therapy/medical necessity criteria for others
    Ankylosing spondylitis and other indications — Inflectra/Renflexis listed with links to criteria or 'None' for step therapy where applicable
    Avastin and biosimilars (Zirabev Q5118, Avastin J9035, Alymsys Q5126) — step therapy criteria and links to criteria/fax forms are provided per agent
    ScopeProvider action
    Many drugs and categories (e.g., SCIG/IVIG, PD1/PDL1 oncology agents, multiple myeloma therapies) are explicitly labeled 'subject to step therapy'
    Providers must follow the linked step therapy criteria and submit required fax request forms or documentation when indicated
    Failure to complete required step therapy or provide required documentation may result in coverage denial for non-preferred products
    Drug / ClassIndications subject to step therapy
    Octreotide acetate depot / Sandostatin LAR / Signifor LAR (J2353, J2502) — listed under systemic indications with links to criteria; 'not required' or links to criteria noted per product
    Systemic lupus erythematosus agents (Benlysta J0490, Saphnelo J0491) — entries reference links to criteria and fax forms; step therapy applicability shown
    VEGF inhibitors (ophthalmic) and bevacizumab (Avastin C9257/J7999, Byooviz Q5124, Eylea J0178/J0177) — marked 'Indications subject to step therapy' with product-level criteria and fax form links
    Viscosupplements (Durolane J7318, Synvisc-one J7325, Gel-one J7326, Monovisc J7327, Hymovis J7322, etc.) — many entries note step therapy or link to criteria and indicate whether prior authorization is required

    Biosimilar Preferences and Notes

    Billing Rule

    Neulasta and related CSF biosimilars — PA/preferred status per listing

    For colony stimulating factors and long‑acting CSFs, certain biosimilars are listed as preferred or as not requiring prior authorization where noted; providers should verify PA status per the linked criteria.

    • Neulasta and biosimilars (Fulphila Q5108, Fylnetra Q5130, Nyvepria Q5122) include entries noting PA status and links to criteria/fax forms.
    • Some long‑acting CSF entries show 'Prior authorization is' or 'not required' — check the specific product listing.
    Billing Rule

    Remicade — preferred/non‑preferred & code mappings

    Remicade and its biosimilars are presented with HCPCS/Q‑code mappings and varying preferred status; provider billing must use the mapped code and follow linked medical necessity criteria for authorization.

    Background and Scope

    Background: medically administered Medicare Part B drugs listed here span multiple therapeutic classes (for example, alpha-1 proteinase inhibitors, bone resorption inhibitors, botulinum toxins, complement inhibitors, colony stimulating factors, enzyme replacement therapies, immunologics and biologics, IV iron, IVIG/SCIG, MS agents, and oncology biologics). The policy uses step therapy and linked medical necessity criteria to manage preferred versus non-preferred product coverage for Aetna Medicare Advantage members.

    Definitions and Key Terms

    Step therapy — definition
    DefinitionA utilization management approach requiring trial of preferred drug(s) before coverage of a non-preferred alternative; an exception process is available for cases that may call for a non-preferred product.
    PurposeTo require use of listed preferred products first; if the preferred product fails, a non-preferred product may be covered per criteria.
    Provider actionProviders must follow the referenced step therapy criteria documents on Aetna's website for specific drug/indication rules and may request exceptions as appropriate.
    Remicade and biosimilars (category)
    Document label'Remicade and biosimilars' is a group label used in the policy to list Remicade (infliximab) and its biosimilars together with HCPCS/Q-code mappings and links to medical necessity and step therapy criteria.
    Included codes/examples

    Policy Revision History

    2025policy_publicationLatest

    Aetna Medicare Advantage Part B preferred drug list policy document published (document code Y0001_NR_4168512_2025_C 4168504-01-01).

    Policy Summary
    PayerAetna
    PolicyMedicare Part B preferred drug list — Aetna Medicare Advantage (MA) only plans
    Policy CodePolicy Y0001_NR_4168512_2025_C 4168504-01-01
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit required medical necessity criteria and the specified fax request form when requesting non-preferred or step therapy‑subject Part B drugs.
    SourceLink
    On This Page
    Coverage Criteria and General Policy RulesHCPCS/Q-code mappings and Code ListsWhat Providers Must Do (Prior Auth, Step Therapy, Fax Forms)Initial Therapy and Step RequirementsStep Therapy Tables and SequencesBiosimilar Preferences and NotesBackground and ScopeDefinitions and Key TermsPolicy Revision History
    Examples linking to criteria
    Many drugs (e.g., Zoledronic acid, Jubbonti, Prolia, Avsola) reference 'Link to criteria' for step therapy — follow the linked criteria document for exact requirements.
    J9155 — category / umbrella mapping
    Umbrella HCPCS mappingJ9155 is used as an umbrella/category HCPCS code in the immunologics/infusions listings (examples: Entyvio IV and multiple infliximab biosimilar entries reference J9155).
    Remicade biosimilars mappingInflectra and Renflexis are mapped alongside J9155-grouped immunologics in the Remicade/biosimilars sections (Q5103, Q5104 appear in same groupings).
    Product cross-referencesSeveral immunologic agents are presented within the J9155 category with per-agent links to medical necessity/step therapy criteria and fax forms (e.g., Avsola Q5121 referenced in J9155 group).
    Prior authorization not required — IV iron examples
    Sodium ferric gluconate (J2916)Prior authorization is not required for sodium ferric gluconate (HCPCS J2916).
    Infed (J1750)Infed (HCPCS J1750) is listed as prior authorization not required.
    Venofer (J1756)Venofer (HCPCS J1756) is listed as prior authorization not required.
    • Eligard (J9217) — “Prior authorization is not required” noted in the Eligard product entry.
    • When an entry lists “Link to criteria” or a fax form, submit per those instructions if PA is required.
    Prior Authorization

    Check linked medical necessity criteria/fax forms for biosimilars and HCPCS-coded agents

    PA requirements vary across biosimilars and HCPCS-coded agents; many Remicade/biosimilar entries (Inflectra Q5103, Renflexis Q5104, Avsola Q5121, Remicade J1745) include links to medical necessity criteria and fax request forms — providers must follow those links for authorization instructions.

    • Inflectra (Q5103) and Renflexis (Q5104) — “Medical necessity criteria = Link to criteria” and fax forms referenced.
    • Remicade (J1745) and Avsola (Q5121) — entries reference linked criteria and fax request form for PA decisions.
    Prior Authorization

    Examples of agents listed as 'PA not required' — verify entry-level guidance

    The policy lists several examples where prior authorization is not required (e.g., bortezomib/Velcade J9046/J9048/J9049; Alimta J9305 in some entries). When PA status is not explicit, consult the product-level link to criteria or fax form before billing/administration.

    • Bortezomib/Velcade (J9046/J9048/J9049) — product entry indicates “Prior authorization is not required.”
    • Alimta (J9305) — check the product entry and linked criteria for PA instructions when listed.
    Prior Authorization

    Consult linked criteria and fax forms for HCPCS-coded PA requirements

    For HCPCS-coded drugs the policy frequently points to a linked medical necessity criteria page and a fax request form; providers must consult those linked documents to determine and submit any required prior authorization.

    • Many oncology, biosimilar and ophthalmic HCPCS entries include “Link to criteria” and “Link to fax form” — use those links when submitting PA requests.
    • If an HCPCS entry does not explicitly state “Prior authorization is not required,” assume PA may be required and follow the linked criteria/fax process.
    Step Therapy

    Follow step therapy: try preferred product(s) first

    Where step therapy applies, providers must use preferred products first; coverage of non-preferred products generally requires documentation of trial/failure of preferred agents or an approved exception.

    • The policy states: “The listed preferred products should be used first... An exception process is in place for specific cases that may call for a non-preferred product.”
    • Step therapy criteria and the required trial/failure sequence are provided in linked step therapy criteria documents for each drug/indication.
    Step Therapy

    Verify whether the specific indication is subject to step therapy

    Step therapy is applied to multiple listed indications and drug classes (examples include Hemophilia A prophylaxis and immunologic indications under J9155); check the product entry for whether the indication is “subject to step therapy.”

    • Hemophilia A (prophylaxis) — factor VIII entries are labeled “Indications subject to step therapy.”
    • Immunologics (J9155) — ulcerative colitis and Crohn’s disease entries show preferred products and note step therapy applicability.
    Step Therapy

    Follow product-level step therapy flags and linked criteria

    Numerous product entries across categories are explicitly labeled “subject to step therapy” or “Indications subject to step therapy” and include links to step therapy criteria; providers must follow the linked step therapy pathways where indicated.

    • Remicade and biosimilars entries (Inflectra, Renflexis, Avsola) include step therapy flags or links to step therapy criteria.
    • Ophthalmic VEGF inhibitors and oncology biosimilars similarly reference step therapy criteria via links in their entries.
    Step Therapy

    Interpret 'Step therapy criteria = None' vs linked step therapy criteria

    Many entries explicitly state “Indications subject to step therapy” and reference step therapy criteria or linked documents — when an entry provides “Step therapy criteria = None” that indicates no step requirement for that product/indication.

    • Kovaltry (J7211) and Nuwiq (J7209) — entries show “Step therapy criteria = None” for Hemophilia A prophylaxis (preferred agents).
    • If an entry lists step therapy criteria via a link, providers must follow that linked criteria for coverage determinations.
    Step Therapy

    Adhere to step therapy sequences defined in linked criteria

    Multiple drugs and categories are marked “Indications subject to step therapy” and the policy points providers to linked step therapy criteria that define required prior trials and failure definitions required for coverage of non-preferred agents.

    • Bevacizumab (Avastin) ophthalmic use is noted with specific PA/step therapy language — see the Avastin entry.
    • For specific sequences (for example trial of bevacizumab before second-tier agents), follow the referenced step therapy criteria documents.
    Documentation Required

    Use the linked medical necessity criteria and fax forms for PA submissions

    Providers must use the document’s referenced medical necessity criteria pages and fax request forms when submitting prior authorization requests; many product entries include explicit “Link to criteria” and “Link to fax form” instructions.

    • Entyvio (J3380), Inflectra (Q5103) and many others list “Prior authorization is not required” OR “Medical necessity criteria = Link to criteria” — follow the listed link or fax form per the entry.
    • When an entry includes a fax request form link, submit that fax form with the medical necessity documentation for authorization decisions.
    Documentation Required

    Submit required medical necessity criteria and fax request forms listed in product entries

    Several product lines (examples: Kovaltry J7211, Nuwiq J7209, Entyvio J3380, Inflectra Q5103) include links to medical necessity criteria and fax request forms — send the specified documents as part of the authorization request.

    • Kovaltry and Nuwiq (Hemophilia A) — “Medical necessity criteria = Link to criteria” and “Fax request form = Link to fax form.”
    • Entyvio and Inflectra (IBD/immunologic indications) — entries reference criteria links and fax forms for PA processing.
    Documentation Required

    Provide the referenced criteria and fax form with authorization requests

    Many agents explicitly reference “Link to criteria” and “Link to fax form”; the policy requires submission of the referenced medical necessity criteria and the fax request form when requesting authorization for non-preferred or step therapy-subject drugs.

    • Remicade/biosimilar and oncology biosimilar entries often include both a criteria link and a fax request form — include both as instructed.
    • If an entry indicates “Prior authorization is not required,” no fax form is required; otherwise submit per the entry’s fax instruction.
    Documentation Required

    Required submission of product-specific criteria and fax form

    Multiple product entries indicate the provider must submit the specified medical necessity criteria and the associated fax request form when requesting coverage for non-preferred or step therapy-subject drugs; failure to provide those documents may prevent authorization.

    • For oncology biosimilars and many biologics the entry shows “Link to criteria” plus “Fax request form = Fax request form” — include both in PA submission.
    • When an entry lists “Step therapy criteria = Link to criteria,” documentation showing trial/failure of preferred agent(s) should accompany the fax form.
    Documentation Required

    Follow product entries’ required documentation and fax forms

    Entries across the policy reference medical necessity criteria and specific fax request forms for many drugs; providers must follow those referenced documents and submit required fax forms when applicable to support authorization decisions.

    • Ophthalmic VEGF, viscosupplement and other category entries include explicit fax form links — follow them for PA or coverage support.
    • If an individual product entry states “not required,” the linked fax form is not necessary for PA; otherwise include the fax form per the entry.
    Denial Risk

    Risk of denial if step therapy is not completed before using a non-preferred drug

    Using a non-preferred Part B drug without completing required step therapy (trial/failure of preferred products) or obtaining an approved exception may result in denial of coverage.

    • The policy explains: “The listed preferred products should be used first... An exception process is in place for specific cases that may call for a non-preferred product.”
    • If step therapy is required and documentation of prior trial/failure or an approved exception is not provided, coverage for the non-preferred drug may be denied.
    Prior Authorization

    PA requirements depend on the specific product entry

    Prior authorization requirements are conditional on the product: some entries explicitly state “Prior authorization is not required” (e.g., Eligard J9217) while adjacent or related products may require PA via linked criteria — check each product entry.

    • Eligard (J9217) — “Prior authorization is not required.”
    • Lupron depot (J9217/J1950) and other gonadotropin-releasing hormone agonists show links to criteria/fax forms — follow product-level guidance.
    Prior Authorization

    IV iron: note which products do or do not require PA

    Certain IV iron products are explicitly listed as not requiring prior authorization (sodium ferric gluconate J2916; Infed J1750; Venofer J1756). Other IV iron agents (Feraheme, Injectafer, Monoferric) reference step therapy/criteria links and may require PA.

    • Sodium ferric gluconate (J2916) — “Prior authorization is not required.”
    • Infed (J1750) and Venofer (J1756) — each entry shows “Prior authorization is not required.”
    • Feraheme (Q0139/Q0138), Injectafer (J1439), Monoferric (J1437) — entries reference step therapy/criteria links and fax forms.
    Denial Risk

    Denial risk if required criteria or fax form are not provided

    Requests that do not include required step therapy documentation, medical necessity criteria, or the specified fax request form (when listed) may be denied; many non-preferred oncology biosimilars and biologics reference criteria/fax requirements for authorization.

    • Oncology biosimilars and Avastin-related entries often show “Link to criteria” and “Fax request form = Fax request form” — missing those items increases denial risk.
    • Rituxan and other biologics list linked criteria and fax forms; include the referenced documentation to reduce denial risk.
    Prior Authorization

    Note Avastin ophthalmic PA note; verify other entries individually

    Bevacizumab (Avastin) is explicitly noted as not requiring prior authorization for indicated ophthalmic uses; however, many other drugs and categories reference medical necessity criteria and fax forms — where “not required” is not stated, follow the linked criteria.

    • Bevacizumab (Avastin) — “Medical necessity criteria = Prior authorization is not required” for the listed Avastin ophthalmic entry.
    • For Avastin biosimilars and other oncology entries, check the product row for links to criteria and fax forms before assuming PA is not required.

    Initial therapy / step therapy notes

    Initial therapy and step therapy notes are provided per product/category.

    Step therapy presence: Some agents explicitly state 'Step therapy criteria = None' (e.g., Inflectra, Renflexis for certain indications); others point to a 'Link to criteria' for step therapy requirements.see product step therapy link

    No explicit step-fail/failover logic present in these chunks; follow linked criteria for details

    PD1/PDL1 initial therapy (refer to linked criteria)

    PD1/PDL1 agents initial therapy notes (refer to linked criteria for full rules)

    PD1/PDL1 initial: PD1/PDL1 agents (e.g., Keytruda J9271, Libtayo J9119) are listed with HCPCS mappings and reference 'Link to criteria' for exact initial therapy and step therapy rules.

    See per-agent criteria links for indication-specific step therapy requirements

    Initial therapy notes (examples)

    Where specified, initial therapy rules or prior authorization status are indicated per drug.

    Bevacizumab (Avastin): Bevacizumab (Avastin, C9257 / J9035) is noted as 'Prior authorization is not required' for indicated uses; other agents list linked medical necessity criteria to determine initial coverage.

    See linked criteria for required prior trials or step therapy

  1. Inflectra mapped to Q5103 and Renflexis to Q5104 with links to criteria and fax forms.
  2. Remicade (J1745) entries reference linked criteria and step therapy rules for non‑preferred mapping.
  3. Billing Rule

    Inflectra (Q5103) — mapped to Remicade biosimilars with criteria links

    Inflectra (Q5103) is mapped as a Remicade biosimilar and linked to medical necessity criteria; some Inflectra entries indicate 'Step therapy criteria = None' for preferred indications but providers must follow the linked criteria when present.

    • Inflectra (Q5103) — 'Medical necessity criteria = Link to criteria' and 'Step therapy criteria = None' in several preferred‑drug entries.
    • Use Q5103 for Inflectra billing and submit the referenced criteria/fax form when required.
    Billing Rule

    Renflexis (Q5104) — mapped to Remicade biosimilars with criteria links

    Renflexis (Q5104) is mapped as a Remicade biosimilar and linked to medical necessity criteria; some entries show 'Step therapy criteria = None' for preferred use, but linked criteria/fax forms govern authorization where shown.

    • Renflexis (Q5104) — 'Medical necessity criteria = Link to criteria' and 'Fax request form = Link to fax form' are shown in the Remicade/biosimilars listings.
    • Bill using Q5104 and follow the referenced criteria for PA where applicable.
    Billing Rule

    Avsola (Q5121) — mapped & linked to criteria/fax form

    Avsola (Q5121) is included in the Remicade/biosimilar group and is linked to medical necessity criteria and a fax request form — providers must use those links for authorization submissions.

    • Avsola, Q5121 — 'Medical necessity criteria = Link to criteria' and 'Fax request form = Link to fax form' in the Remicade group.
    Billing Rule

    Zirabev (Q5118) — Avastin biosimilar with criteria/step therapy links

    Zirabev (Q5118) is listed under the Avastin/biosimilar group with link(s) to medical necessity criteria and step therapy; verify and follow the linked criteria and fax form for authorization.

    • Zirabev mapped to Q5118 — 'criteria = Link to criteria' and 'Link to fax form' are included in the Avastin listings.
    • Avastin group entries include step therapy criteria and require adherence to linked rules for non‑preferred agents.
    Billing Rule

    Byooviz (Q5124) and other VEGF biosimilars — follow mapped codes & criteria

    Referent VEGF inhibitor biosimilars such as Byooviz (Q5124) are listed with HCPCS mappings and links to medical necessity criteria; provider submissions must follow the linked criteria and any stated step therapy.

    • Byooviz (Q5124) — 'Medical necessity criteria = Link to criteria' and 'Fax request form = Link to fax form' in the Avastin/VEGF inhibitor listings.
    • Preference sequencing and step therapy rules are provided in the linked criteria documents.
    Examples in this category include Remicade (J1745) and biosimilars Inflectra (Q5103), Renflexis (Q5104), Avsola (Q5121).
    Authorization referencesEntries under this label reference 'Link to criteria' and a fax request form for authorization where applicable; some biosimilars note 'Step therapy criteria = None'.
    IVIG / SCIG — category definition
    Category definitionIVIG / SCIG denotes intravenous and subcutaneous immunoglobulin product categories with listed HCPCS codes and referenced medical necessity and step therapy criteria.
    Representative HCPCS codesExamples include J1561 (Gammaked/Gamunex-C) and J1459 (Privigen) for IVIG; SCIG entries also appear with J-codes and fax forms referenced.
    Authorization linkageIVIG/SCIG product entries reference medical necessity criteria and fax request forms — providers must use the linked criteria/forms when authorization is required.
    PD1/PDL1 — class definition
    Class descriptionPD1/PDL1 refers to programmed cell death protein 1 / ligand 1 inhibitors used for oncology indications (examples: squamous cell carcinoma, non-small cell lung cancer); agents are listed with J-codes and step therapy references.
    ExamplesPD1/PDL1 agents referenced include Keytruda (J9271), Libtayo (J9119) and other mapped J-codes in the PD1/PDL1 category listings.
    Authorization notesPD1/PDL1 entries point to step therapy and medical necessity criteria links for indication-specific authorization rules; consult linked criteria for details.